English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [1826]
News [2737]
Articles [202]
Editorials [1]
Conferences [136]
elearning [13]
How pancreatic cancer defies treatment
How pancreatic cancer defies treatment
Stress-tolerant cells drive tumour initiation in pancreatic cancer
Stress-tolerant cells drive tumour initiation in pancreatic cancer
Slit2 signalling stimulates Ewing sarcoma growth
Slit2 signalling stimulates Ewing sarcoma growth
Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer
Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer
Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients
Technique for tracking resistant cancer cells could lead to new treatments for relapsing breast cancer patients
A double bind for cancer
A double bind for cancer
ASH 2022: New results from the phase 3 GLOW study of fixed-duration treatment with ibrutinib plus venetoclax demonstrate robust efficacy and sustained response in older, unfit patients with previously untreated chronic lymphocytic leukaemia
ASH 2022: New results from the phase 3 GLOW study of fixed-duration treatment with ibrutinib plus venetoclax...
ASH 2022: Venetoclax with CLIA highly effective in younger patients with newly diagnosed AML and high-risk MDS
ASH 2022: Venetoclax with CLIA highly effective in younger patients with newly diagnosed AML and high-risk MDS
ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back
ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back
SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer
SABCS 2022: Camizestrant may be superior to fulvestrant in hormone receptor-positive, HER2-negative breast cancer
<1...3839404142...274>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top